NASDAQ : ADXN
Addex Therapeutics Ltd — Key statistics
Healthcare · Biotechnology · Switzerland
Last price 3.09 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.35M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 6.01M |
| Enterprise Value | 5.17M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 127.41M |
| Shares Change (YoY) | +19.49% |
| Shares Change (QoQ) | +3.43% |
| Owned by Insiders (%) | 10.10% |
| Owned by Institutions (%) | 0.98% |
| Float | 198.16M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 58.81 |
| Forward PS | n/a |
| PB Ratio | 2.56 |
| P/TBV Ratio | 2.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 50.67 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.76 |
| Quick Ratio | 0.58 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -818.35 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -150.58% |
| Return on Assets (ROA) | -27.12% |
| Return on Invested Capital (ROIC) | -35.19% |
| Return on Capital Employed (ROCE) | -122.88% |
| Weighted Average Cost of Capital (WACC) | 15.17% |
| Revenue Per Employee | $34,269 |
| Profits Per Employee | -$2.83M |
| Employee Count | 3 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.02 |
| 52-Week Price Change | -67.37% |
| 50-Day Moving Average | 3.33 |
| 200-Day Moving Average | 6.05 |
| Relative Strength Index (RSI) | 49.00 |
| Average Volume (20 Days) | 6,073 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5,613 |
| Short Previous Month | 1,840 |
| Short % of Shares Out | 0.36% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.35 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 102,808 |
| Gross Profit | -336,853 |
| Operating Income | -3.22M |
| Pretax Income | -8.50M |
| Net Income | -8.50M |
| EBITDA | -3.22M |
| EBIT | -3.22M |
| Loss Per Share | -$8.46 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 949,663 |
| Total Debt | 95,910 |
| Net Cash | 853,754 |
| Net Cash Per Share | $0.01 |
| Equity (Book Value) | 2.36M |
| Book Value Per Share | 0.02 |
| Working Capital | -403,920 |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -2.89M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | -4,363 |
| Net Borrowing | -45,955 |
| Free Cash Flow | -2.89M |
| FCF Per Share | -$0.02 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -3,130.68% |
| Pretax Margin | -8,266.91% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -19.49% |
| Shareholder Yield | -19.49% |
| Earnings Yield | -275.53% |
| FCF Yield | -47.85% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 23, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -146.51 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |